Market Closed -
Nasdaq
21:30:01 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.68
USD
|
-4.55%
|
|
-9.19%
|
+16.67%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10.55
|
4.466
|
4.777
|
-
|
-
|
Enterprise Value (EV)
1 |
10.55
|
4.466
|
4.777
|
4.777
|
4.777
|
P/E ratio
|
-1.96
x
|
-1.2
x
|
-3
x
|
-2.4
x
|
-2.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
61.9
x
|
66.4
x
|
66.4
x
|
66.4
x
|
EV / Revenue
|
-
|
61.9
x
|
66.4
x
|
66.4
x
|
66.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,139
|
3,101
|
2,844
|
-
|
-
|
Reference price
2 |
3.360
|
1.440
|
1.680
|
1.680
|
1.680
|
Announcement Date
|
24/03/23
|
25/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0721
|
0.072
|
0.072
|
0.072
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-3.856
|
-4.47
|
-9.386
|
-16.82
|
Operating Margin
|
-
|
-5,347.56%
|
-6,208.33%
|
-13,036.11%
|
-23,356.94%
|
Earnings before Tax (EBT)
1 |
-
|
-3.631
|
-4.04
|
-8.926
|
-16.32
|
Net income
1 |
-3.909
|
-3.701
|
-4.04
|
-8.926
|
-16.32
|
Net margin
|
-
|
-5,132.7%
|
-5,611.11%
|
-12,397.22%
|
-22,673.61%
|
EPS
2 |
-1.710
|
-1.202
|
-0.5600
|
-0.7000
|
-0.7200
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/23
|
25/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
0.018
|
0.018
|
EBITDA
|
-
|
-
|
EBIT
1 |
-0.7734
|
-1.164
|
Operating Margin
|
-4,289.52%
|
-6,454.35%
|
Earnings before Tax (EBT)
1 |
-0.6602
|
-1.052
|
Net income
1 |
-0.6602
|
-1.121
|
Net margin
|
-3,661.45%
|
-6,218.41%
|
EPS
2 |
-0.2100
|
-0.3816
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
13/11/23
|
25/03/24
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/23
|
25/03/24
|
-
|
-
|
-
|
Last Close Price
1.68
USD Average target price
10
USD Spread / Average Target +495.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.67% | 4.78M | | -2.61% | 89.08B | | +3.55% | 40.9B | | -14.40% | 32.25B | | +55.89% | 25.14B | | -15.96% | 15.39B | | -15.50% | 11.91B | | -41.29% | 11.89B | | -11.75% | 11.64B | | +7.87% | 9.03B |
Biopharmaceuticals
|